Catalog No.
Product Name
Application
Product Information
Citations
-
KSP Inhibitor
Ispinesib (SB-715992) is a potent inhibitor of kinesin spindle protein, a kinesin motor protein essential for the formation of a bipolar mitotic spindle and cell cycle progression through mitosis. -
KSP inhibitor
KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5) with potential antineoplastic activity. -
Mps1 inhibitor
AZ 3146 is a potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM). It interferes with chromosome alignment and overrides spindle assembly checkpoint and also Inhibits the recruitment of Mad1, Mad2 and centromere protein E (CENP-E) to kinetochores.
- Junna Tanaka, .et al. , Cell Signal, 2024, Jul:119:111172 PMID: 38604342
- Ryuzaburo Yuki, .et al. , Eur J Pharmacol, 2024, Jan 15:963:176229 PMID: 38072041
- Ryoko Ota, .et al. , Cell Signal, 2023, Sep;109:110764 PMID: 37315749
- Ryuzaburo Yuki, .et al. , J Cell Mol Med, 2021, Feb;25(3):1677-1687 PMID: 33465289
- Yamagishi A, .et al. , Int J Mol Sci, 2020, Feb 5;21(3) PMID: 32033461
- Kakihana A, .et al. , FASEB J, 2018, Nov 29:fj201801369R PMID: 30496702
- Suzuki M, .et al. , Anticancer Res, 2016, Jun;36(6):2783-92 PMID: 27272789
-
CENP-E inhibitor
GSK-923295, is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E, (CENP-E).- Amber S Zhou, .et al. , PLoS Biol, 2023, Oct 26;21(10):e3002339 PMID: 37883329
-
TTK inhibitor
CFI-402257, a pyrazolopyridin derivative, has been found to be a TTK inhibitor that could influence chromosome segregation and induce cell death so that is significant in anticancer studies.- Jian Yu, .et al. , BMC Cancer, 2022, Jul 18;22(1):786 PMID: 35850753
-
Mps1 inhibitor
MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 -
KSP inhibitor
ARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM. -
Kinesin Eg5 inhibitor
Dimethylenastron is an inhibitor of mitotic motor kinesin Eg5 with IC50 value of 200 nM. -
kinesin Eg5 inhibitor
Eg5 Inhibitor V, trans-24 is a potent and specific kinesin Eg5 inhibitor with an IC50 of 0.65 μM, and can be used in the research of cancer. -
MPS1 checkpoint inhibitor
BOS-172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with an IC50 of 2 nM. -
Kif15 inhibitor
Kif15-IN-2 is an inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases. -
Kif15 inhibitor
Kif15-IN-1 is an inhibitor of the mitotic Kinesin family member 15 (Kif15), and is used for the research of cellular proliferative diseases. -
kinesin Eg5 inhibitor
Litronesib (Racemate) is the racemate of litronesib. Litronesib is a selective, allosteric inhibitor of kinesin Eg5. -
MPS1 kinase inhibitor
BAY 1217389 is a potent, and selective inhibitor of the monopolar spindle 1 (MPS1) kinase with an IC50 value less than 10 nM. -
Mps1 inhibitor
Empesertib (BAY 1161909) is a potent Mps1 inhibitor, with an IC50 of < 1 nM. -
mitosis-specific kinesin Eg5 inhibitor
Litronesib is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activity. -
KIF18A Inhibitor
Sovilnesib is a selective inhibitor of the kinesin-like protein KIF18A, exhibiting an IC50 value of 0.071 μM. This potent, orally active compound is utilized in cancer research, where it aids in the investigation of microtubule dynamics and the mechanisms of tumor cell proliferation. Sovilnesib facilitates the study of KIF18A's role in cancer progression and provides insights into potential therapeutic strategies targeting this protein. -
HSET Inhibitor
CCT368772 is a selective kinesin HSET inhibitor, demonstrating an IC50 value of 0.019 μM in the HSET ADP-Glo assay. This compound shows high selectivity for HSET, with minimal activity against Eg5 (IC50 >200 μM). CCT368772 is suitable for research into hyperproliferative diseases, including various cancer types, providing a valuable tool for understanding and potentially targeting these pathologies. -
KIF18A Inhibitor
KIF18A-IN-6 is a potent inhibitor of KIF18A, exhibiting an IC50 of 0.016 μM against KIF18A's microtubule-dependent ATPase activity. This compound is valuable for investigating the role of KIF18A in cellular processes, including mitotic spindle assembly and chromosome alignment. Researchers can utilize KIF18A-IN-6 to explore therapeutic strategies targeting cancer cell division by modulating KIF18A activity. -
KIF18A Inhibitor
KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A, demonstrating significant anti-tumor activity. By targeting KIF18A, this compound has the potential to activate mitotic checkpoints, selectively inducing apoptosis in chromosomally unstable cancer cells. It is a valuable tool for research focused on cancer biology and the development of targeted cancer therapeutics. -
KIF18A Inhibitor
AM-5308 is a potent inhibitor of KIF18A, showcasing an IC50 value of 47 nM. By inhibiting KIF18A-mediated microtubule ATPase activity, AM-5308 effectively activates mitotic checkpoints and regulates critical cell division processes, including chromosome segregation and spindle assembly. This compound demonstrates notable antitumor activity, making it a valuable tool for cancer research and studies focused on mitotic regulation. -
KIF18A Inhibitor
AM-9022 is a potent and selective inhibitor of KIF18A, primarily targeting the kinesin family of motor proteins involved in cellular transport and mitosis. This compound demonstrates significant inhibitory activity, making it a valuable tool for research into cancer mechanisms and potential therapeutic strategies. Its efficacy in modulating KIF18A function provides insights into the role of mitotic regulation in tumorigenesis. -
Kinesin-5 Inhibitor
PVZB1194 is a selective inhibitor of Kinesin-5 ATPase, targeting the α4/α6 site within the motor domain in a nucleotide-competitive manner. With an IC50 of 0.12 μM for KSP ATPase, PVZB1194 effectively induces mitotic arrest characterized by the formation of monopolar spindles, leading to inhibition of HeLa cell proliferation (IC50: 5.5 μM). This compound is valuable for research applications focusing on tumor biology and cell division regulation. -
CENP-E Inhibitor
PF-2771 is a selective inhibitor of centromere protein E (CENP-E) that inhibits its motor activity with an IC50 of 16.1 nM. This compound exhibits significant potential as an anticancer agent by disrupting mitotic processes and leading to cell cycle arrest. PF-2771 is utilized in research investigating the mechanisms of cancer cell division and has applications in the development of novel cancer therapeutics. -
KIF18A Inhibitor
KIF18A-IN-13 is a potent inhibitor of KIF18A, demonstrating significant anticancer activity in vivo. This compound is particularly applicable in research focusing on ovarian cancer, providing a valuable tool for studying the mechanisms of tumor growth and potential therapeutic interventions. -
Kinesin
BRD9876 is a kinesin-5 (Eg5) inhibitor that functions by locking the protein in a conformation with enhanced microtubule binding, promoting microtubule bundling and stabilization. It specifically interacts with the tyrosine 104 residue within the α4-α6 allosteric binding pocket of Eg5, selectively inhibiting myeloma cells while sparing CD34+ hematopoietic stem cells. This compound is a valuable tool for studying the mechanisms of multiple myeloma and developing potential therapeutic strategies. -
CENP-E Inhibitor
Syntelin is a selective inhibitor of centromere protein E (CENP-E) with an IC50 of 160 nM. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its ability to modulate CENP-E function underscores its potential applications in studying mitotic processes and exploring therapeutic strategies for cancer treatment. -
KIFC1 Inhibitor
SR31527 chloride is a potent inhibitor of KIFC1, exhibiting an IC50 value of 6.6 µM. This compound effectively reduces cell viability and impairs colony formation in cellular assays. Its biological activity makes it a valuable tool for investigating the roles of KIFC1 in cell proliferation and cancer research. -
KIF18A Inhibitor
KIF18A-IN-2 is a selective inhibitor of KIF18A with an IC50 of 28 nM. This compound effectively induces mitotic arrest, leading to an increased population of mitotic cells in tumor tissues. KIF18A-IN-2 is suitable for use in cancer research, providing valuable insights into the mechanisms of cell division and the potential for therapeutic interventions. -
KIF18A Inhibitor
KIF18A-IN-3 is a selective inhibitor of kinesin motor protein KIF18A, with an IC50 of 61 nM. This compound induces significant mitotic arrest and enhances the population of mitotic cells within tumor tissues. KIF18A-IN-3 is suited for cancer research applications, providing insights into the roles of mitotic regulation and potential therapeutic strategies targeting KIF18A. -
KIF18A Inhibitor
KIF18A-IN-9 is a potent inhibitor of kinesin family member 18A (KIF18A), exhibiting an IC50 value of 3.8 nM. This compound demonstrates significant anticancer activity, showing IC50 values below 100 nM in ovarian cancer OVCAR3 and breast cancer MDA-MB-157 cell lines. KIF18A-IN-9 serves as a valuable tool for investigating the role of KIF18A in mitotic processes and its potential therapeutic implications in cancer research. -
KSP Inhibitor
Filanesib TFA is a selective kinesin spindle protein (KSP) inhibitor, demonstrating an IC50 of 6 nM against human KSP. This compound effectively induces apoptosis in vitro, providing potent anti-proliferative activity. Filanesib TFA is utilized in research applications focused on cancer biology and exploring novel therapeutic strategies targeting mitotic processes. -
Eg5 Inhibitor
(S)-Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5, known for its ability to disrupt mitotic spindle formation. This compound exhibits significant antiproliferative activity against various cancer cell lines by inducing a monopolar spindle formation, effectively arresting mammalian cells in mitosis. (S)-Monastrol serves as a valuable tool for research into cancer biology and the mechanisms of cell division. -
Eg5 Inhibitor
SB-743921 free base is a highly selective inhibitor of the mitotic kinesin Eg5, exhibiting a Ki of 0.1 nM. This compound effectively induces mitotic arrest, inhibits cell cycle progression, and promotes apoptosis. It serves as a valuable tool in cancer research, particularly in the study of myeloma, leukemia, and other malignancies. -
Anticancer Agent
Kolavenic acid analog (KAA) is an anticancer agent that inhibits centrosome clustering in human cancer cells characterized by elevated levels of HSET and supernumerary centrosomes. KAA demonstrates significant activity against HSET-overproducing yeast cells, making it a valuable tool for understanding the role of HSET in cancer biology. This compound is suitable for research applications targeting centrosome dynamics and their implications in tumorigenesis. -
HSET Motor Inhibitor
Solidagonic acid is an HSET motor inhibitor that facilitates the conversion of abnormal monopolar spindles to bipolar spindles, thus promoting proper mitotic progression. This compound has been shown to suppress cell death in fission yeast and can revert monopolar to bipolar spindle morphology. Additionally, Solidagonic acid demonstrates growth inhibitory effects on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam, making it a valuable tool for studying spindle dynamics and plant development. -
KIF18A Inhibitor
KIF18A-IN-4 is a noncompetitive inhibitor of KIF18A, targeting ATP and microtubule interactions with an IC50 of 6.16 μM. This compound demonstrates selectivity against a wide range of mitotic kinesins and kinases, while not interfering with tubulin assembly. KIF18A-IN-4 is valuable for research applications focused on tumor biology, particularly in studies investigating its anti-tumor properties. -
MKLP2 Inhibitoe
LG157 is a potent inhibitor of mitotic kinesin-like protein 2 (MKLP2), a critical motor protein involved in maintaining mitotic spindle dynamics and cytokinesis. By selectively targeting MKLP2, LG157 effectively disrupts cell division, making it a valuable reagent for research into cancer cell proliferation and related therapeutic strategies. Its application in cell biology provides insight into the mechanisms of mitotic regulation and potential treatment approaches for tumors exhibiting aberrant cell division.
